Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8017)
All Articles published online
|
Publishing Process of This Article
|
Aug 16, 2018 (publication date) through Apr 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases 2018; 6(8): 161-166 [PMID: 30148143 DOI: 10.12998/wjcc.v6.i8.161] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v6/i8/161.htm |
| Number | Citing Articles |
| 1 |
Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh. Biosimilars in Oncology: Latest Trends and Regulatory Status. Pharmaceutics 2022; 14(12): 2721 doi: 10.3390/pharmaceutics14122721
|
| 2 |
Satish Shilpi, Ekta Gurnany, Pawan K. Gupta, Kangan Sharma, Khyati Saini, Pranali Chimaniya, Shvetank Bhatt. Biosimilars for Cancer Treatment. 2024; : 35 doi: 10.1007/978-981-97-3001-8_3
|
| 3 |
Aqsa Safdar, Muhammad Hammad Butt, Abrar Ahmad, Muhammad Zaman. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies. Journal of Oncology Pharmacy Practice 2021; 27(5): 1195 doi: 10.1177/10781552211016083
|
| 4 |
Kritika Gupta, Ranjeet Desai, Ketki Jawade, Dhanashree D. Jagtap, Deepak Modi, Ratnesh Jain, Prajakta Dandekar. Determination of functional similarity of biosimilar H9P2S from an investigational CHO clone with Adalimumab. 3 Biotech 2022; 12(11) doi: 10.1007/s13205-022-03384-z
|
| 5 |
Shadi Askari, Alireza Ghofrani, Hamed Taherdoost. Transforming Drug Design: Innovations in Computer-Aided Discovery for Biosimilar Agents. BioMedInformatics 2023; 3(4): 1178 doi: 10.3390/biomedinformatics3040070
|
| 6 |
Simon W Lam, Kevin Amoline, Christopher Marcum, Mandy Leonard. Healthcare system conversion to a biosimilar: Trials and tribulations. American Journal of Health-System Pharmacy 2021; doi: 10.1093/ajhp/zxab279
|
| 7 |
Xinyi Xu, Shengzhao Zhang, Ting Xu, Mei Zhan, Chen Chen, Chenyu Zhang. Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.880090
|
| 8 |
Ying Gao, David Gervais. Overcoming challenges of improving legacy biopharmaceutical processes. Journal of Chemical Technology & Biotechnology 2021; 96(5): 1141 doi: 10.1002/jctb.6687
|
| 9 |
Alexey V. Samtsov, Andrey L. Bakulev, Vladislav R. Khairutdinov, Muza M. Kokhan, Tat’yana V. Korotaeva, Iskander K. Minullin, Olga A. Vylegzhanina, Valery V. Dubenskiy, Bulat V. Khalilov, Alkes A. Khotko, Olga S. Zykova, Irina V. Chumachenko, Alexander M. Lukyanov, Antonina V. Artemeva, Polina P. Pukhtinskaia, Yuanyuan Wang. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial. PLOS ONE 2022; 17(2): e0263214 doi: 10.1371/journal.pone.0263214
|
| 10 |
Douglas J. Rupert, Alyssa M. Jordan, Marina A. Ziemian, Rachel M. Brown, Neil S. Fleming, R. Craig Lefebvre. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study. BioDrugs 2022; 36(5): 645 doi: 10.1007/s40259-022-00545-7
|
| 11 |
John Hair, Thomas Maryon, Cristian Lieneck. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption. Medicina 2022; 58(11): 1533 doi: 10.3390/medicina58111533
|
| 12 |
Dipali Dongare, Anika Rana, Shireen Nishad, Pratima Tripathi. Biosimilars for Cancer Treatment. 2024; : 1 doi: 10.1007/978-981-97-3001-8_1
|
| 13 |
Shubha Bhat, Sarah Altajar, Divya Shankar, Toni Zahorian, Regine Robert, Taha Qazi, Bhavesh Shah, Francis A. Farraye. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. Journal of Managed Care & Specialty Pharmacy 2020; 26(4): 410 doi: 10.18553/jmcp.2020.26.4.410
|
| 14 |
Jennifer Fenna, Daniel McCormack, Sophie Kitchen, Diana Martins, Tara Gomes, Mina Tadrous. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. Journal of Managed Care & Specialty Pharmacy 2021; 27(4): 444 doi: 10.18553/jmcp.2021.27.4.444
|
| 15 |
Jasmine Lee, Anastasios Panagiotelis, Rose Cairns, Nial J. Wheate. An analysis of the trends in the usage of Pharmaceutical Benefits Scheme-subsidised cancer drugs in Australia from 2012 to 2022. Journal of Cancer Research and Clinical Oncology 2024; 150(8) doi: 10.1007/s00432-024-05889-x
|
| 16 |
Mohamed Izham Mohamed Ibrahim, Ahmed Awaisu. Global Pharmaceutical Policy. 2020; : 53 doi: 10.1007/978-981-15-2724-1_3
|
| 17 |
Seema Yadav, Narahari Narayan Palei, Subas Chandra Dinda, Arghya Kusum Dhar. Concepts in Pharmaceutical Biotechnology and Drug Development. Interdisciplinary Biotechnological Advances 2024; : 103 doi: 10.1007/978-981-97-1148-2_7
|
| 18 |
Peter J. Choi, Thomas I−H. Park, Elizabeth Cooper, Mike Dragunow, William A. Denny, Jiney Jose. Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope. Bioconjugate Chemistry 2020; 31(7): 1724 doi: 10.1021/acs.bioconjchem.0c00302
|
| 19 |
Priyal Patel, Yash Patel, Samir Gunvantbhai Patel, Archita Samir Patel, Arvind Ganpule, Sachchida Nand Pandey. Biosimilars for Cancer Treatment. 2024; : 97 doi: 10.1007/978-981-97-3001-8_6
|
| 20 |
Nayana Hitesh Patel, Niket H. Patel, Molina Niket Patel, Harsha K. Bhadarka, Kairavi Sunilkumar Vyas. Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study. Journal of Human Reproductive Sciences 2023; 16(2): 148 doi: 10.4103/jhrs.jhrs_37_23
|
| 21 |
Yeong Wook Song, Yong-Beom Park, Jinseok Kim. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 2021; 21(1): 1 doi: 10.1080/14712598.2020.1701650
|
| 22 |
Bárbara Peliçário Vargas, Marcel Henrique Marcondes Sari, Luana Mota Ferreira. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars. Anti-Cancer Agents in Medicinal Chemistry 2022; 22(14): 2507 doi: 10.2174/1871520622666220302114313
|
| 23 |
Juan David Rosas Cabrera, Carlos Andrés Díaz Rodríguez. Pichia pastoris as a biological platform to produce recombinant proteins: relevance for development of biotechnological products in Colombia. Revista de la Facultad de Ciencias 2021; 10(1): 20 doi: 10.15446/revfaccienc.v10n1.86805
|
| 24 |
Viraj A Shinde, Ramanand Patil, Prasan Bhandari, Prachitee Borkar, Shraddha Yadav. A Pharmacoeconomic Outlook of the Biological Drugs Marketed in India: A Cost Variance Analysis. Cureus 2023; doi: 10.7759/cureus.33943
|
| 25 |
Obinna N. Obianom, Olanrewaju O. Okusanya, Justin Earp, Theingi M. Thway. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies. Clinical Pharmacology & Therapeutics 2020; 108(1): 107 doi: 10.1002/cpt.1767
|
| 26 |
J. Posner, P. Barrington, T. Brier, A. Datta-Mannan. Concepts and Principles of Pharmacology. Handbook of Experimental Pharmacology 2019; 260: 81 doi: 10.1007/164_2019_323
|
| 27 |
Rachel N. Israilevich, Kannan Sharma, Matthew R. Starr. Biosimilars for Retinal Diseases: A Review of the Literature. International Ophthalmology Clinics 2024; 64(1): 129 doi: 10.1097/IIO.0000000000000509
|
| 28 |
Pallavi M. Chaudhari, Pranav Shah, Harita Desai, Neha Raghuvanshi, Bhagwat Patil. Biosimilars for Cancer Treatment. 2024; : 241 doi: 10.1007/978-981-97-3001-8_14
|
| 29 |
A. Abitbol, L. Chu. What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives. Diabetes, Obesity and Metabolism 2025; doi: 10.1111/dom.16278
|
| 30 |
Ravi Shankar, Monika Joshi, Sonal Mehrotra, Vijay Sharma, Kamla Pathak. Physico-Chemical Aspects of Dosage Forms and Biopharmaceutics. 2024; : 211 doi: 10.1016/B978-0-323-91818-3.00015-3
|
| 31 |
Gauri Pathak, Aryaa Nigade, Dishank Purandare, Vaishnavi Thorat, Shvetank Bhatt. Biosimilars for Cancer Treatment. 2024; : 229 doi: 10.1007/978-981-97-3001-8_13
|
| 32 |
Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology 2019; 84(1): 83 doi: 10.1007/s00280-019-03850-1
|
| 33 |
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Futang Yang, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu. Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial. The Breast 2025; 80: 104413 doi: 10.1016/j.breast.2025.104413
|
| 34 |
Nikola A. Ivica, Colin M. Young. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020). Healthcare 2021; 9(8): 1062 doi: 10.3390/healthcare9081062
|
| 35 |
Kuttiappan Anitha, Shvetank Bhatt, Santenna Chenchula, Girdhari Lal Gupta, Ravindra Babu Pingili. Biosimilars for Cancer Treatment. 2024; : 143 doi: 10.1007/978-981-97-3001-8_8
|
| 36 |
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Greg Kricorian, James L. O’Kelly, Walter Reinisch. Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848231222332
|
| 37 |
Mingzhu Cao, Yuqi Hu, Jiaqi Xiao, Sichen Li, Yanshan Lin, Jianqiao Liu, Haiying Liu. Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1358278
|
| 38 |
Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals. Therapies 2022; 77(4): 467 doi: 10.1016/j.therap.2021.10.012
|
| 39 |
Sofia Konstantinidou, Angeliki Papaspiliou, Eleni Kokkotou. Current and future roles of biosimilars in oncology practice (Review). Oncology Letters 2019; doi: 10.3892/ol.2019.11105
|
| 40 |
Manvi Singh, Pratima R. Solanki. Biomedical Product and Materials Evaluation. 2022; : 275 doi: 10.1016/B978-0-12-823966-7.00007-4
|